# Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment

> **NCT03941587** · NA · COMPLETED · sponsor: **Singapore National Eye Centre** · enrollment: 60 (actual)

## Conditions studied

- Polypoidal Choroidal Vasculopathy

## Interventions

- **DRUG:** Aflibercept + reduced fluence photodynamic therapy (RF-PDT)
- **DRUG:** Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)

## Key facts

- **NCT ID:** NCT03941587
- **Lead sponsor:** Singapore National Eye Centre
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-01
- **Primary completion:** 2024-06-06
- **Final completion:** 2024-06-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03941587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03941587, "Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03941587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*